Cybin Inc.

NYSE American CYBN

Cybin Inc. Interest Coverage Ratio for the year ending March 31, 2024

Cybin Inc. Interest Coverage Ratio is NA for the year ending March 31, 2024. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.

Cybin Inc. Interest Coverage Ratio for the year ending March 31, 2022 was -264.89, a 91.78% change year over year.
Cybin Inc. Interest Coverage Ratio for the year ending March 31, 2021 was -3,221.00.

Key data

Date	Interest Coverage Ratio	Debt to Equity Ratio	Interest Expense To Sales	Inventory Turnover Ratio

NYSE American: CYBN

Cybin Inc.

CEO	Mr. Douglas L. Drysdale
IPO Date	Sept. 13, 2019
Location	Canada
Headquarters	100 King Street West
Employees	50
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.

Key trends

Past 5 years